Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease

Trial Profile

Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Spesolimab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Feb 2019 Status changed from not yet recruiting to recruiting.
    • 22 Jan 2019 Planned initiation date changed from 14 Jan 2019 to 5 Feb 2019.
    • 09 Jan 2019 Planned initiation date changed from 4 Jan 2019 to 14 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top